PL2554541T3 - Środek terapeutyczny lub środek profilaktyczny na fibromialgię - Google Patents

Środek terapeutyczny lub środek profilaktyczny na fibromialgię

Info

Publication number
PL2554541T3
PL2554541T3 PL11765736T PL11765736T PL2554541T3 PL 2554541 T3 PL2554541 T3 PL 2554541T3 PL 11765736 T PL11765736 T PL 11765736T PL 11765736 T PL11765736 T PL 11765736T PL 2554541 T3 PL2554541 T3 PL 2554541T3
Authority
PL
Poland
Prior art keywords
agent
fibromyalgia
prophylactic
therapeutic agent
therapeutic
Prior art date
Application number
PL11765736T
Other languages
English (en)
Inventor
Chihiro Yoshida
Kaoru Nakao
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2554541T3 publication Critical patent/PL2554541T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11765736T 2010-03-31 2011-03-31 Środek terapeutyczny lub środek profilaktyczny na fibromialgię PL2554541T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010083721 2010-03-31
EP11765736.1A EP2554541B1 (en) 2010-03-31 2011-03-31 Therapeutic agent or prophylactic agent for fibromyalgia
PCT/JP2011/058218 WO2011125836A1 (ja) 2010-03-31 2011-03-31 線維筋痛症の治療剤又は予防剤

Publications (1)

Publication Number Publication Date
PL2554541T3 true PL2554541T3 (pl) 2016-06-30

Family

ID=44762774

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11765736T PL2554541T3 (pl) 2010-03-31 2011-03-31 Środek terapeutyczny lub środek profilaktyczny na fibromialgię

Country Status (13)

Country Link
US (1) US8957094B2 (pl)
EP (1) EP2554541B1 (pl)
JP (1) JP5751168B2 (pl)
KR (1) KR101738471B1 (pl)
CN (1) CN102822148B (pl)
AU (1) AU2011237072B2 (pl)
BR (1) BR112012022947B1 (pl)
CA (1) CA2793709C (pl)
ES (1) ES2562470T3 (pl)
MX (1) MX2012010767A (pl)
PL (1) PL2554541T3 (pl)
RU (1) RU2560168C2 (pl)
WO (1) WO2011125836A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021002784B1 (pt) * 2010-04-28 2021-08-31 Toray Industries, Inc Agente terapêutico ou agente profilático para a doença de alzheimer
MX2013000946A (es) * 2010-07-30 2013-02-27 Toray Industries Agente terapeutico o agente profilactico para el dolor neuropatico.
JPWO2014088106A1 (ja) * 2012-12-06 2017-01-05 株式会社PRISM Pharma 線維筋痛症の予防または治療薬
MX367576B (es) 2014-01-29 2019-08-27 Toray Industries Agente terapéutico o profiláctico para esclerosis múltiple.
US9725473B2 (en) * 2015-07-28 2017-08-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
WO2017096148A1 (en) * 2015-12-03 2017-06-08 Katz Robert S Methods and systems for diagnosing and treating fibromyalgia
JP7036724B2 (ja) 2016-07-29 2022-03-15 日本たばこ産業株式会社 ピラゾール-アミド化合物の製造方法
WO2018181859A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 抗がん剤誘発末梢神経障害の治療剤又は予防剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
WO2000066562A1 (en) * 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
CA2497951A1 (en) * 2002-09-05 2004-03-18 Scios Inc. Treatment of pain by inhibition of p38 map kinase
JPWO2007111323A1 (ja) * 2006-03-27 2009-08-13 東レ株式会社 ウレイド誘導体およびその医薬用途
EP2061775A2 (en) * 2006-09-13 2009-05-27 Astra Zeneca AB Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
US20080171762A1 (en) * 2007-01-16 2008-07-17 Ockert David M Treatment of pain with naloxone
WO2008105383A1 (ja) * 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途

Also Published As

Publication number Publication date
MX2012010767A (es) 2012-10-15
CA2793709C (en) 2017-09-12
JPWO2011125836A1 (ja) 2013-07-11
EP2554541A4 (en) 2013-10-09
CA2793709A1 (en) 2011-10-13
JP5751168B2 (ja) 2015-07-22
KR20130052536A (ko) 2013-05-22
RU2012146325A (ru) 2014-05-10
BR112012022947A2 (pt) 2020-07-28
RU2560168C2 (ru) 2015-08-20
US20130190503A1 (en) 2013-07-25
BR112012022947B1 (pt) 2021-06-15
KR101738471B1 (ko) 2017-05-22
EP2554541A1 (en) 2013-02-06
CN102822148B (zh) 2015-03-11
ES2562470T3 (es) 2016-03-04
AU2011237072B2 (en) 2014-09-04
CN102822148A (zh) 2012-12-12
WO2011125836A1 (ja) 2011-10-13
AU2011237072A1 (en) 2012-10-18
EP2554541B1 (en) 2015-12-09
US8957094B2 (en) 2015-02-17

Similar Documents

Publication Publication Date Title
SG10201506840QA (en) Cytotoxicity-inducing therapeutic agent
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
ZA201409186B (en) Therapeutic agent or prophylactic agent for dementia
IL226181A0 (en) inhaler
EP2510949A4 (en) THERAPEUTICS FOR FIBROMYALGIA
EP2554541A4 (en) THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR FIBROMYALGIA
PL2529739T3 (pl) Środek terapeutyczny lub profilaktyczny na choroby dróg żółciowych
PL2723344T3 (pl) Złożony środek leczniczy zawierający monoterpen
IL245995A0 (en) Prophylactic or medical agent for fibrosis
IL220850B (en) Anti- or alleviation of pigmentation
ZA201206957B (en) Sterilising apparatus
PL2599487T3 (pl) Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
GB201005394D0 (en) Therapy
GB201016864D0 (en) Therapeutic methods
PL2637748T3 (pl) Armatura bezpieczeństwa
EP2629766A4 (en) COMBINATION THERAPY
IL226574A (en) Processes for making anamines
GB201003727D0 (en) Therapeutic agent
GB201011456D0 (en) Compositions and methods for embolization therapy
GB201018104D0 (en) Projection apparatus
GB201119761D0 (en) Examing procedure